- Home
- Products
Retevmo (Selpercatinib)
Retevmo (Selpercatinib)
- Medicine Name: Retevmo
- Generic Name: Selpercatinib
- Dosage Form & Strength: Capsules – 40 mg, 80 mg
- Manufactured By: Eli Lilly and Company
Retevmo is a selective RET kinase inhibitor used for the treatment of:
- Adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
- Adults and children (12+ years) with RET-mutant medullary thyroid cancer (MTC) requiring systemic therapy
- Adults and children (12+ years) with RET fusion-positive thyroid cancer refractory to radioactive iodine (if appropriate)
Recommended Dosage
- <50 kg: 120 mg twice daily
- ≥50 kg: 160 mg twice daily
- Take Retevmo approximately every 12 hours, with or without food
- Swallow whole – do not crush or chew
- Missed dose: If more than 6 hours have passed, skip it
- Vomiting after dose: Do not retake, continue as scheduled
Hepatotoxicity: Monitor ALT/AST before starting, every 2 weeks (first 3 months), then monthly
Hypertension: Regular BP checks recommended
QT Interval Prolongation: Use caution in patients at risk (e.g., with long QT syndrome or heart failure)
Hemorrhagic Events: May be life-threatening – discontinue if severe bleeding occurs
Wound Healing Impairment: Avoid Retevmo around major surgeries (before and after)
Documents Required to Import Retevmo to India
- Valid doctor’s prescription
- Diagnostic reports confirming RET fusion or mutation
- Government-issued ID proof
Order Confirmation
Orders are confirmed only after:
- Receipt of valid prescription
- Import permit (if applicable)
Availability
Retevmo is available in India through Global Rare Meds in cities including:
Mumbai, Delhi, Noida, Gurgaon, Bangalore, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Lucknow, Chandigarh, Jaipur, Ludhiana, Srinagar, Jammu – and more.
📞 Contact for Pricing & Orders
WhatsApp/Call: +91-99675 15602
Email: info@globalraremeds.com
- Sourced from certified suppliers across the USA, Europe, Canada & Australia
- Fulfilled from our facility in Ambernath, Thane District
- Handled by licensed pharmacists and shipped directly to patients’ addresses
- Fully compliant with WHO-GDP and ISO quality standards
What is the generic name of Retevmo®?
Selpercatinib
Who manufactures Retevmo®?
Eli Lilly and Company
When was Retevmo® approved by the FDA?
May 8, 2020
What cancers does Retevmo® treat?
- RET fusion-positive NSCLC
- RET-mutant medullary thyroid cancer
- RET fusion-positive thyroid cancer (radioactive iodine-refractory)
What forms is Retevmo® available in?
- Capsules: 40 mg, 80 mg
- Newly approved tablets: 40 mg, 80 mg, 120 mg, 160 mg
Are capsules and tablets interchangeable?
The transition to tablets is ongoing. Tablets will eventually replace capsules. Patients must follow doctor guidance when switching.
What are common side effects?
High BP, rash, fatigue, diarrhea, constipation, dry mouth, reduced blood counts, increased cholesterol/creatinine levels
How much does Retevmo® cost in India?
Cost varies based on strength, supply location, and brand source. Contact us on WhatsApp at +91-99675 15602 for accurate pricing.
How should Retevmo® be stored?
Store at 20°C to 25°C (68°F to 77°F). Excursions allowed between 15°C to 30°C. Keep in original packaging.
Is Retevmo available in Asia?
Yes, including India, Bangladesh, Nepal, Pakistan, Sri Lanka, Bhutan, Maldives, and Afghanistan
Are there new approvals or expanded indications?
Yes. Retevmo is now approved for pediatric patients ≥2 years old for RET+ advanced thyroid cancers. New tablet form approved for easier dosing.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
